Monatsschrift Kinderheilkunde

, Volume 154, Issue 9, pp 910–911

Langwirksame β2-Sympathomimetika

Gefahren in der Asthmatherapie ?
  • D. Reinhardt
  • D. Berdel, A. Schuster, A. von Berg, M. Gappa, F. Friedrichs, J. Freihorst, J. Forster, F. Riedel, E. Rietschel, Christoph Runge, R. Szczepanski, W. Wahlen, U. Wahn
Leserforum
  • 29 Downloads

Literatur

  1. 1.
    Anderson HR, Aytes JG, Sturdy PM et al. (2005) Bronchodilator treatment and deaths from asthma: case-control study. BMJ 330: 117–119CrossRefPubMedGoogle Scholar
  2. 2.
    Ärztliches Zentrum für Qualität in der Medizin (ÄZQ) (2005) Nationale Versorgungsleitlinie Asthma. Dt Ärztebl 40: B2307–B2311Google Scholar
  3. 3.
    Barnes PJ (1995) Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 152: 838–860PubMedGoogle Scholar
  4. 4.
    Bateman ED, Boushey HA, Bousquet J et al. (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL (GOAL) study. Am J Respir Crit Care Med (in press)Google Scholar
  5. 5.
    Berdel et al. AWMF-S2- Leitlinie Asthma bronchiale im Kindesalter. AWMF-Leitlinien-Register Nr. 026/010Google Scholar
  6. 6.
    Bisgaard H (2000) Long-acting β2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 29: 221–234CrossRefPubMedGoogle Scholar
  7. 7.
    Bisgaard H (2003) Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 36: 391–398CrossRefPubMedGoogle Scholar
  8. 8.
    Bisgaard H, Szefler S (2006) Long-acting beta2-agonists and paediatric asthma. Lancet 367: 286–288CrossRefPubMedGoogle Scholar
  9. 9.
    British Thoracic Society (2003) The british guidelines on asthma management. Asthma in adults and schoolchildren. Thorax 58: 1–94CrossRefGoogle Scholar
  10. 10.
    Buhl R, Berdel D, Criee C-P et al. (2006) Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Pneumologie 60: 139–183CrossRefPubMedGoogle Scholar
  11. 11.
    Castle W, Fuller R, Hall J, Palmer J (1993) Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306: 1034–1037PubMedGoogle Scholar
  12. 12.
    Fahy JV, Boushey HA (1995) Controversies involving inhaled beta-agonists and inhaled corticosterids in the treatment of asthma. Clin Chest Med 16: 715–733 PubMedGoogle Scholar
  13. 13.
    Gillissen A, Jaworska M, Schärling B, van Zwoll D, Schultze-Werninghaus G (1996) b2-agonists have antioxidant function in vitro (part I). Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Respiration (accepted)Google Scholar
  14. 14.
    Lurie P, Wolfe SM (2005) Misleading data analysis in salmeterol (SMART) study. Lancet 366: 1261–1262 CrossRefPubMedGoogle Scholar
  15. 15.
    Mann M, Chowdhury BA, Sullivan EJ, Nicklas R, Anthracite R, Meyer RJ (2003) Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124: 70–74CrossRefPubMedGoogle Scholar
  16. 16.
    Maris NA, Vos de AF, Dessing MC et al. (2005) Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 172: 878–884 CrossRefPubMedGoogle Scholar
  17. 17.
    Martinez FD (2005) Safety of long-acting beta-agonists – an urgent need to clear the air. N Engl J Med 353: 2637–2639CrossRefPubMedGoogle Scholar
  18. 18.
    McCoy L, Redelings M, Sorvillo F, Simon P (2005) A multiple cause-of-death analysis of asthma mortality in the United States, 1990-2001. J Asthma 42: 757–763 CrossRefPubMedGoogle Scholar
  19. 19.
    National Institutes of Health (Hrsg) (2005) Global strategy for asthma management and prevention NHLBI/WHO Workshop report. Bethesda, USA: U.S. Department of Health and Human Services: 1–176 (http://www.ginasthma.com)Google Scholar
  20. 20.
    Nelson HS (2006) Is there a problem with inhalaed long-acting β-adrenergic agonists ? J Allergy Clin Immunol 117: 3–16 CrossRefPubMedGoogle Scholar
  21. 21.
    Nelson HS, Weiss ST, Bleeker ER, Yancey SW, Dorinsky PM (2006) The salmeterol mulicenter asthma research trial. A comparision of usal pharmacotherapy for asthma or usal pharmacotherapy plus salmeterol. Chest 129: 15–26CrossRefPubMedGoogle Scholar
  22. 22.
    O’Byrne PM, Ädelroth E (2006) β2 déjà vu. Chest 129: 3–5 CrossRefPubMedGoogle Scholar
  23. 23.
    O’Connor BJ, Aikman SL, Barnes PJ (1992) Tolerance to the nonbronchodilator effects of inhaled beta2-agonists in asthma. N Engl J Med 328: 665–666Google Scholar
  24. 24.
    Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S (2006) The arginine-16 beta 2 adrenoceptor genotype predisposis to exacerbations in young asthmatics taking regular salmeterol. Thorax e-publication Google Scholar
  25. 25.
    Pauwels RA, Calverley PMA, Vestbo J et al. (2002) Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstrucitve pulmonary diasease (COPD) (abst.). Eur Respir J 20: 241sGoogle Scholar
  26. 26.
    Pauwels RA, Löfdahl C-G, Postma DS et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337: 1405–1411 CrossRefPubMedGoogle Scholar
  27. 27.
    Rickard KA (2005) Misleading data analysis in salmeterol (SMART) study: GlaxoSmithklin’s reply. Lancet 366: 1262CrossRefGoogle Scholar
  28. 28.
    Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (2006) Meta-Analysis: Effect of long-acting β-agonists on severe-asthma exacerbations and asthma-related deaths. Ann Intern Med 144: 904–912PubMedGoogle Scholar
  29. 29.
    Salpeter SR, Ormiston TM, Salpeter EE (2004) Meta-analysis: respiratory tolerance to regular β2-agnoist use in patients with asthma. Ann Intern Med 140: 802–813PubMedGoogle Scholar
  30. 30.
    Sears M (2000) Consequences of long-term inflammation. The natural history of asthma. Clin Chest Med 21: 315–329CrossRefPubMedGoogle Scholar
  31. 31.
    Sears MR, Taylor DR, Print CG et al. (1990) Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336: 1391–1396CrossRefPubMedGoogle Scholar
  32. 32.
    Suissa S, Ernst P, Benayoun S, Baltzan M, Sci B (2000) Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343: 332–336CrossRefPubMedGoogle Scholar
  33. 33.
    Suissa S, Hemmelgarn B, Blais L, Ernst P (1996) Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 154: 1598–1602PubMedGoogle Scholar
  34. 34.
    Tal A, Simon G, Vermeulen JH et al. (2002) Budesonid/Formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 34: 342–350CrossRefPubMedGoogle Scholar
  35. 35.
    Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF (1998) Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 158: 213–219 PubMedGoogle Scholar
  36. 36.
    Wechsler ME, Israel E (2005) How pharmacogenomics will play a role in the management of asthma. Am J Respir Crit Care Med 172: 12–18 CrossRefPubMedGoogle Scholar
  37. 37.
    Wolfe J, LaForce CF, Sokol W, Orevillo C, Till D (2006) Formoterol, 24 µg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 µg bid, with and without extra doses taken on demand, and placebo. Chest 129: 27–38CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  • D. Reinhardt
    • 1
  • D. Berdel, A. Schuster, A. von Berg, M. Gappa, F. Friedrichs, J. Freihorst, J. Forster, F. Riedel, E. Rietschel, Christoph Runge, R. Szczepanski, W. Wahlen, U. Wahn
  1. 1.Dr. von Haunersches KinderspitalKlinikum der LMU MünchenMünchenDeutschland

Personalised recommendations